Krystal Biotech KRYS · NASDAQ
$320.25 +1.16% (+$3.67)
Summary
74 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 55 USD is left as net profit.
- It holds more cash than debt: $427.7M against $8.85M.
- It earns 15 USD a year on every 100 USD of invested capital.
- Analysts expect revenue to grow by 28% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 39.3 USD for 1 USD of yearly profit. Over the last five years it was 134.4 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 28%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 6.7 USD
- Research and development 13 USD
- Sales and administration 35 USD
- Taxes and other -9.9 USD
- Net profit 55 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 55 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 17
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $395.2 is 23% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.